Przejdź do zawartości
Merck

P-011

Supelco

(+)-Propoxyphene solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Wzór empiryczny (zapis Hilla):
C22H29NO2
Numer CAS:
Masa cząsteczkowa:
339.47
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
NACRES:
NA.24

klasa czystości

certified reference material

Postać

liquid

Właściwości

Snap-N-Spike®/Snap-N-Shoot®

opakowanie

ampule of 1 mL

producent / nazwa handlowa

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

stężenie

1.0 mg/mL in acetonitrile

metody

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Zastosowanie

forensics and toxicology

format

single component solution

temp. przechowywania

2-8°C

ciąg SMILES

CCC(=O)O[C@@](Cc1ccccc1)([C@H](C)CN(C)C)c2ccccc2

InChI

1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1

Klucz InChI

XLMALTXPSGQGBX-GCJKJVERSA-N

informacje o genach

human ... OPRM1(4988)

Opis ogólny

A certified Snap-N-Spike® solution standard suitable for propoxyphene testing methods by GC/MS or LC/MS in pain prescription monitoring, clinical toxicology, urine drug testing, or forensic analysis. Propoxyphene, also known as dextropropoxyphene, is an opioid analgesic drug intended for treatment of mild pain. In combination with either paracetamol or aspirin, dextropropoxyphene is sold under trade names including Darvocet-N® and Darvon®.

Informacje prawne

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Darvocet-N is a registered trademark of AAIPharma LLC
Darvon is a registered trademark of Xanodyne Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
This page may contain text that has been machine translated.

Piktogramy

FlameExclamation mark

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

Klasyfikacja zagrożeń

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Kod klasy składowania

3 - Flammable liquids

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

35.6 °F - closed cup

Temperatura zapłonu (°C)

2 °C - closed cup


Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Suicides involving co-proxamol fell dramatically after withdrawal in UK.
Zosia Kmietowicz
BMJ (Clinical research ed.), 344, e3255-e3255 (2012-05-11)
Margareeta Häkkinen et al.
Forensic science international, 222(1-3), 327-331 (2012-08-14)
There is a rising trend of fatal poisonings due to medicinal opioids in several countries. The present study evaluates the drug and alcohol findings as well as the cause and manner of death in opioid-related post-mortem cases in Finland from
W Stephen Waring et al.
Clinical toxicology (Philadelphia, Pa.), 49(6), 452-456 (2011-08-10)
The Medicines and Healthcare products Regulatory Authority (MHRA) is the government body with responsibility for regulating new and existing medicines and medical devices in the United Kingdom. The Yellow Card scheme is a well-established pharmacovigilance system that collects voluntary reports
Robert B Raffa et al.
Expert opinion on pharmacotherapy, 13(10), 1397-1409 (2012-05-10)
d-Propoxyphene, which was previously available in many single-agent and combination products, was recently voluntarily withdrawn from the US market following an FDA recommendation based partly on the concern that the risk associated with QT prolongation exceeded the clinical benefit of
Yatan Pal Singh Balhara et al.
Journal of opioid management, 8(1), 45-49 (2012-04-07)
In view of increasing safety concerns, there is a need to assess benefits of use of dextropropoxyphene as opioid substitution treatment, if any. This study aims at urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej